Skip to main content
TRAX logo

TRAX · First Tracks Biotherapeutics, Inc. · Metrics

Track TRAX — free
$44.79 +0.29 (+0.65%)
Market Cap
$1.87B
Shares
42.02M
Volume · Nov 19 98.53K Avg daily vol (3M) 827.63K

TRAX metrics

52 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$44.50
Market cap
$1.87B

Price action

23 metrics
Price change (1W)
-11.9%
Price change (30D)
+22.7%
Price change (3M)
-2.2%
Price change (6M)
+175.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
122.5%
Annualized volatility (3M)
74.3%
Implied volatility (30D)
93.7%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.4
RSI (14D)
50.2
Price vs SMA 50
+10.8%
Price vs SMA 200
—
Avg volume (3M)
827,612
Relative volume
0.9
Average dollar volume
$32.62M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
42.02M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
12.4
reciprocal yield 8.1%
FCF yield
-5.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-12

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$157.36M
Net income (TTM)
−$149.80M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+28.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-99.2%
Return on assets
-87.9%
Debt / equity
0.0
Current ratio
9.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$110.17M
Quick ratio
9.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$155.63M
Latest balance sheet
Cash & equivalents
$155.63M
Total assets
$170.46M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$110.12M
Capital expenditures (TTM)
$43,000
R&D (TTM)
$109.00M
SG&A (TTM)
—
Stock compensation (TTM)
$35.77M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
182
13F filer change QoQ
+32
Institutional ownership
86.2%
Conviction holders (share of 13F filers)
2.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.5%
Holder tenure
1.9
Price vs estimated holder cost
+52.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.8%

Short interest

3 metrics
Short interest
12.0%
Latest settlement · 6.5 days to cover
Days to cover
6.5d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.76M
Insider-sentiment score
26 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2091349 CUSIP 337185102 13F (30d) 178 filings 175 filers Visit website Investor relations